Prostate Cancer Prevention by n-3 Unsaturated Fatty Acids
n-3 不饱和脂肪酸预防前列腺癌
基本信息
- 批准号:7086318
- 负责人:
- 金额:$ 53.23万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2005
- 资助国家:美国
- 起止时间:2005-06-28 至 2009-04-30
- 项目状态:已结题
- 来源:
- 关键词:apoptosisbiomarkercancer preventionclinical researchclinical trialsdiet therapydietary supplementshuman subjecthuman therapy evaluationhuman tissuemalemarine animal oilnutrition aspect of cancernutrition related tagomega 3 fatty acidoncoproteinspatient oriented researchphosphorylationprostate neoplasmstranslation factor
项目摘要
DESCRIPTION (provided by applicant): Epidemiological evidence highlights the influence of n-3 polyunsaturated fatty acids (PUFAs) on the incidence of prostate cancer. In a 12-year prospective population study of about 50,000 men, consumption of fish, a rich source of n-3 PUFAs, three times per week halved the risk of metastatic prostate cancer. Work by the applicants has identified the molecular mechanism of the anti-cancer effect of EPA, the main marine n-3 PUFA: EPA causes Ca++-stores mediated phosphorylation of the translation initiation factor elF2alpha and thereby inhibition of mRNA translation at the initiation level. This results in preferential downregulation of oncogenic proteins leading to cell cycle arrest in the G1 phase and to increased expression of translationally regulated pro-apoptotic proteins. Daily administration of EPA increased the life expectancy of mice bearing orthotopic xenograph human prostate tumors, and doubled the life expectancy of p53 -/ mice. Phosphorylation of elF2alpha, the critical molecular mediator of the anti-cancer action of EPA, can be readily detected with anti-phosphorylated elF2alpha-specific antibodies in prostate cancer cells, in prostate xenograph tumors and in the human prostate. Thus, phosphorylated elF2alpha, the primary endpoint of the studies in this application, can be used as a molecular biomarker of the translation-initiation inhibitory activity of EPA in prostate cancers. Our hypothesis is that consumption of diets rich in marine n-3 PUFAs exerts anti-prostate cancer activity because they reduce the expression of translationally regulated oncogenic proteins and increase expression of translationally regulated pro-apoptotic proteins. To test this hypothesis, we will: 1) conduct a prospective randomized placebo-controlled intervention study to determine whether oral daily administration of distilled fish oil (70% EPA) before surgery induces phosphorylation of elF2alpha in prostate tumors; 2) determine the correlation between the fatty acid composition of the diet, as determined by fatty acid analysis of red blood cells, with the levels of elF2alpha phosphorylation and Gleason score in prostate biopsies; and 3) conduct a retrospective study using an available collection of prostate tumors linked to 10 years follow-up clinical data to analyze the correlation between elF2alpha phosphorylation in the tumors, their Gleason score and the time to PSA failure. As secondary endpoint in all studies we will correlate both clinical parameters of prostate cancer with the expression of translationally regulated oncogenic proteins such as Ras, c-myc and cyclin D1, and of pro-apoptotic proteins such as CHOP. This effort will provide a strong cellular and molecular basis for the promotion of dietary interventions to increase n-3 PUFAs for the prevention of prostate cancer.
描述(由申请方提供):流行病学证据强调了n-3多不饱和脂肪酸(PUFA)对前列腺癌发病率的影响。在一项为期12年的前瞻性人群研究中,约有50,000名男性,每周三次食用鱼,一种丰富的n-3 PUFA来源,转移性前列腺癌的风险减半。本申请人的工作已经确定了EPA(主要的海洋n-3 PUFA)抗癌作用的分子机制:EPA导致翻译起始因子eIF 2 α的Ca++-储存介导的磷酸化,从而在起始水平抑制mRNA翻译。这导致致癌蛋白的优先下调,从而导致细胞周期停滞在G1期,并增加了诱导调节的促凋亡蛋白的表达。EPA的每日给药增加了原位异种移植人前列腺肿瘤小鼠的预期寿命,并使p53 -/小鼠的预期寿命加倍。EPA抗癌作用的关键分子介体eIF 2 α的磷酸化可以在前列腺癌细胞、前列腺异种移植肿瘤和人前列腺中用抗磷酸化eIF 2 α特异性抗体容易地检测。因此,磷酸化eIF 2 α(本申请中研究的主要终点)可用作前列腺癌中EPA的预防起始抑制活性的分子生物标志物。我们的假设是,食用富含海洋n-3 PUFAs的饮食发挥抗前列腺癌活性,因为它们减少了调节性致癌蛋白的表达,并增加了调节性促凋亡蛋白的表达。1)进行前瞻性随机安慰剂对照干预研究,以确定手术前每日口服蒸馏鱼油(70%EPA)是否诱导前列腺肿瘤中eIF 2 α的磷酸化; 2)确定饮食的脂肪酸组成之间的相关性,如通过红细胞的脂肪酸分析所确定的,与前列腺活组织检查中eIF 2 α磷酸化水平和Gleason评分相关;和3)使用与10年随访临床数据相关的前列腺肿瘤的可用集合进行回顾性研究,以分析肿瘤中eIF 2 α磷酸化、其Gleason评分和PSA失败时间之间的相关性。作为所有研究的次要终点,我们将前列腺癌的临床参数与凋亡调节的致癌蛋白(如Ras、c-myc和细胞周期蛋白D1)和促凋亡蛋白(如CHOP)的表达相关联。这项工作将为促进饮食干预以增加n-3 PUFA预防前列腺癌提供强有力的细胞和分子基础。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JOSE A HALPERIN其他文献
JOSE A HALPERIN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JOSE A HALPERIN', 18)}}的其他基金
Blood Levels of Glycated CD59, a Novel Biomarker to Assess Pregnancy-induced Glucose Intolerance
糖化 CD59 的血液水平,一种评估妊娠引起的葡萄糖不耐受的新型生物标志物
- 批准号:
9902416 - 财政年份:2019
- 资助金额:
$ 53.23万 - 项目类别:
Blood Levels of Glycated CD59, a Novel Biomarker to Assess Pregnancy-induced Glucose Intolerance
糖化 CD59 的血液水平,一种评估妊娠引起的葡萄糖不耐受的新型生物标志物
- 批准号:
10599099 - 财政年份:2019
- 资助金额:
$ 53.23万 - 项目类别:
Blood Levels of Glycated CD59, a Novel Biomarker to Assess Pregnancy-induced Glucose Intolerance
糖化 CD59 的血液水平,一种评估妊娠引起的葡萄糖不耐受的新型生物标志物
- 批准号:
10382406 - 财政年份:2019
- 资助金额:
$ 53.23万 - 项目类别:
Human Studies on Blood Levels of Glycated CD59 as a Biomarker in Diabetes
糖化 CD59 血液水平作为糖尿病生物标志物的人体研究
- 批准号:
9116831 - 财政年份:2014
- 资助金额:
$ 53.23万 - 项目类别:
Human Studies on Blood Levels of Glycated CD59 as a Biomarker in Diabetes
糖化 CD59 血液水平作为糖尿病生物标志物的人体研究
- 批准号:
8668411 - 财政年份:2014
- 资助金额:
$ 53.23万 - 项目类别:
Glycated CD59 as a novel biomarker of gestational diabetes mellitus
糖化 CD59 作为妊娠期糖尿病的新型生物标志物
- 批准号:
8374166 - 财政年份:2012
- 资助金额:
$ 53.23万 - 项目类别:
Glycated CD59 as a novel biomarker of gestational diabetes mellitus
糖化 CD59 作为妊娠期糖尿病的新型生物标志物
- 批准号:
8523847 - 财政年份:2012
- 资助金额:
$ 53.23万 - 项目类别:
Glycation inactivation of human CD59 and diabetic complications
人 CD59 的糖基化失活与糖尿病并发症
- 批准号:
8766558 - 财政年份:2011
- 资助金额:
$ 53.23万 - 项目类别:
Glycation inactivation of human CD59 and diabetic complications
人 CD59 的糖基化失活和糖尿病并发症
- 批准号:
8234691 - 财政年份:2011
- 资助金额:
$ 53.23万 - 项目类别:
Glycation inactivation of human CD59 and diabetic complications
人 CD59 的糖基化失活和糖尿病并发症
- 批准号:
8399044 - 财政年份:2011
- 资助金额:
$ 53.23万 - 项目类别:
相似国自然基金
基于DNA甲基化交互网络的癌症hallmark挖掘及其在癌症转移biomarker筛选中的应用
- 批准号:61602201
- 批准年份:2016
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
血清miRNAs成为一种新的biomarker在PD诊断中的价值和LRRK2基因调控的机制研究
- 批准号:81170309
- 批准年份:2011
- 资助金额:50.0 万元
- 项目类别:面上项目
生物标志物NGAL和KIM-1分子在急性肾损伤中的作用机制研究及标志物联合检测对早期诊断AKI的作用
- 批准号:81101308
- 批准年份:2011
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
精神分裂症记忆障碍的脑网络组学研究
- 批准号:91132301
- 批准年份:2011
- 资助金额:350.0 万元
- 项目类别:重大研究计划
卵巢癌血浆microRNA潜在标志物筛选及调控机制研究
- 批准号:81072363
- 批准年份:2010
- 资助金额:32.0 万元
- 项目类别:面上项目
高原人群创伤性深静脉血栓血浆预测诊断蛋白标记物的发掘
- 批准号:81060151
- 批准年份:2010
- 资助金额:25.0 万元
- 项目类别:地区科学基金项目
非小细胞肺癌Biomarker的Imaging MS研究新方法
- 批准号:30672394
- 批准年份:2006
- 资助金额:30.0 万元
- 项目类别:面上项目
相似海外基金
Project 2: TOPK/PRPK as Novel Targets for Skin Cancer Prevention
项目2:TOPK/PRPK作为皮肤癌预防新靶点
- 批准号:
10475138 - 财政年份:2019
- 资助金额:
$ 53.23万 - 项目类别:
Project 2: TOPK/PRPK as Novel Targets for Skin Cancer Prevention
项目2:TOPK/PRPK作为皮肤癌预防新靶点
- 批准号:
10686370 - 财政年份:2019
- 资助金额:
$ 53.23万 - 项目类别:
Project 1: TLR4 as a Novel Target for Skin Cancer Prevention
项目 1:TLR4 作为预防皮肤癌的新靶点
- 批准号:
10475132 - 财政年份:2019
- 资助金额:
$ 53.23万 - 项目类别:
Project 1: TLR4 as a Novel Target for Skin Cancer Prevention
项目 1:TLR4 作为预防皮肤癌的新靶点
- 批准号:
10686367 - 财政年份:2019
- 资助金额:
$ 53.23万 - 项目类别:
Project 1: TLR4 as a Novel Target for Skin Cancer Prevention
项目 1:TLR4 作为预防皮肤癌的新靶点
- 批准号:
10015216 - 财政年份:2019
- 资助金额:
$ 53.23万 - 项目类别:
Project 1: TLR4 as a Novel Target for Skin Cancer Prevention
项目 1:TLR4 作为预防皮肤癌的新靶点
- 批准号:
10252869 - 财政年份:2019
- 资助金额:
$ 53.23万 - 项目类别:
Project 2: TOPK/PRPK as Novel Targets for Skin Cancer Prevention
项目2:TOPK/PRPK作为皮肤癌预防新靶点
- 批准号:
10252870 - 财政年份:2019
- 资助金额:
$ 53.23万 - 项目类别:
Project 2: TOPK/PRPK as Novel Targets for Skin Cancer Prevention
项目2:TOPK/PRPK作为皮肤癌预防新靶点
- 批准号:
10015217 - 财政年份:2019
- 资助金额:
$ 53.23万 - 项目类别:
IGF::OT::IGF EVALUATING INTERMITTENT DOSING OF ASPIRIN FOR COLORECTAL CANCER PREVENTION
IGF::OT::IGF 评估间歇性服用阿司匹林预防结直肠癌的效果
- 批准号:
9369089 - 财政年份:2016
- 资助金额:
$ 53.23万 - 项目类别:
IGF::OT::IGF EVALUATING INTERMITTENT DOSING OF ASPIRIN FOR COLORECTAL CANCER PREVENTION
IGF::OT::IGF 评估间歇性服用阿司匹林预防结直肠癌的效果
- 批准号:
10018590 - 财政年份:2016
- 资助金额:
$ 53.23万 - 项目类别:














{{item.name}}会员




